MedTrace Logo

Topical Tranexamic Acid in Major Paediatric Spine Deformity Surgery: A Randomized Controlled Trial

NCT02093988 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2015-12-02

No results posted yet for this study

Summary

Our study will evaluate the use of topical and intravenous (IV) Tranexamic Acid (TXA) in spine surgery. The purpose of TXA is to prevent clotting during surgery to reduce blood loss. When used intravenously, it has been shown to safe, efficacious, and effective in reducing transfusion requirements and blood loss in spine surgeries. We want to evaluate the effect of using TXA topically and intravenously to see if it further reduces blood loss in children undergoing major surgery compared to IV TXA only

Conditions

  • Spinal Deformity, Paediatric Surgery, Tranexamic Acid

Interventions

DRUG

Topical TXA

DRUG

Intravenous TXA

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Brett Kilb, Md · Resident

  • Firoz Miyanji, MD · Clinical Assistant Professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02093988 on ClinicalTrials.gov